Financial reports
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
1 Mar 22
10-Q
2021 Q3
Quarterly report
4 Nov 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
25 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
Current reports
8-K
Completion of Acquisition or Disposition of Assets
2 Mar 23
8-K
Other Events
14 Feb 23
8-K
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
9 Jan 23
8-K
Departure of Directors or Certain Officers
6 Dec 22
8-K
Albireo Reports Q3 2022 Financial Results and Business Update
8 Nov 22
8-K
Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Alagille Syndrome
11 Oct 22
8-K
Albireo Announces $115 Million Royalty Monetization Agreement with Sagard
22 Sep 22
8-K/A
Departure of Directors or Certain Officers
22 Aug 22
8-K
Entry into a Material Definitive Agreement
15 Aug 22
8-K
Albireo Reports Q2 2022 Financial Results and Business Update
15 Aug 22
Registration and prospectus
15-12G
Securities registration termination
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Mar 23
POS AM
Prospectus update (post-effective amendment)
2 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Mar 23
POS AM
Prospectus update (post-effective amendment)
2 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Mar 23
Proxies
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
PRE 14A
Preliminary proxy
16 Apr 21
DEFA14A
Additional proxy soliciting materials
17 Apr 20
DEF 14A
Definitive proxy
17 Apr 20
DEFA14A
Additional proxy soliciting materials
25 Apr 19
DEF 14A
Definitive proxy
25 Apr 19
DEF 14A
Definitive proxy
24 Apr 18
Other
EFFECT
Notice of effectiveness
9 Mar 23
EFFECT
Notice of effectiveness
9 Mar 23
EFFECT
Notice of effectiveness
9 Mar 23
EFFECT
Notice of effectiveness
9 Mar 23
EFFECT
Notice of effectiveness
9 Mar 23
EFFECT
Notice of effectiveness
26 Aug 22
UPLOAD
Letter from SEC
23 Aug 22
CORRESP
Correspondence with SEC
23 Aug 22
EFFECT
Notice of effectiveness
19 Aug 20
CORRESP
Correspondence with SEC
14 Aug 20
Ownership
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
FEDERATED HERMES, INC.
10 Apr 23
SC 13G/A
BlackRock Inc.
8 Mar 23
4
David Chiswell
3 Mar 23
4
Susan Alesina
2 Mar 23
4
Stephanie Okey
2 Mar 23
4
Simon N.R. Harford
2 Mar 23
4
Ronald Harold Wilfred Cooper
2 Mar 23
4
PAUL STRECK
2 Mar 23
4
Pamela Stephenson
2 Mar 23